Association Identified Between Malnutrition and Post-Operative Outcomes in Gynecologic Cancer


Nutritional markers such as body mass index, weight loss, and albumin should be assessed to identify pre-operative malnutrition in patients with gynecologic cancers.

Cancer-specific malnutrition criteria may help to personalize pre-operative risk assessment in patients with gynecologic cancer, according to a study published in Gynecologic Oncology

Classifications included severe malnutrition—defined as body mass index (BMI) of less than 18.5 to 22 plus 10% weight loss by European Society for Clinical Nutrition and Metabolism (ESPEN1) criteria, BMI 18.5 to 22 plus 10% weight loss, BMI of less than 18.5 by ESPEN2 criteria—or mild malnutrition—defined as BMI 18.5 to 22, or albumin of less than 3.5 g/dL.

Among patients who had ovarian cancer, ESPEN2 malnutrition was associated with higher readmission rates (risk ratio [RR], 1.69; 95% CI, 1.29-2.20), reoperation (RR, 2.53; 95% CI, 1.70-3.77), and major complications (RR, 1.36; 95% CI, 1.20-1.54). Those with uterine cancer who were malnourished based on American Cancer Society (ACS) criteria were more at risk of readmission (RR, 2.74; 95% CI, 2.09-3.59), reoperation (RR, 3.61; 95% CI, 2.29-5.71), and major complications (RR, 3.92; 95% CI, 3.40-4.53). Additionally, for cervical cancer those with albumin levels of less than 3.5 g/dL had higher rates of readmission (RR, 1.48; 95% CI, 1.01-2.19), reoperation (RR, 2.25; 95% CI, 1.17-4.34), and major complications (RR, 2.59; 95% CI, 2.11-3.17).

Investigators identified a total of 76,290 patients met the inclusion criteria, of whom 68.8% had uterine cancer, 23.3% had ovarian cancer, and 7.9% had cervical cancer. About 60% of patients were under 65 years of age, 2.1% were over 85 years, and the 70.3% of patients were White. The median BMI was 31.3 kg/m2 and 1.7% had lost more than 10% of their body weight 6 months prior to surgery. Additionally, 3.7% of patients were mildly malnourished, 0.1% had severe malnutrition, 0.2% had ESPEN1, 1.1% had ESPEN2, and 1.3% had ACS malnutrition.

Overall, the rate of unplanned readmission rate was 5.5%, the reoperation rate was 1.7%, and the major complication rate was 13.5%. A higher risk of unplaced readmission was observed in patients who met criteria for EPEN2 (adjusted RR [aRR], 1.45; 95% CI, 1.17-1.80) and ACS malnutrition (RR, 1.44; 95% CI, 1.19-1.74). Those who met the criteria for severe malnourition criteria (aRR, 3.79; 95% CI, 2.00-7.15) and ESPEN2 criteria (aRR; 1.93; 95% CI, 1.37-2.72) had increased rates of unplanned reoperation.

The most common major complication was blood transfusion in 9.9% of patients. Those who met the ACS definition of malnutrition had higher rates of minor complications (aRR, 1.28; 95% CI, 1.04-1.58). The overall death rate was 0.3% and 96.9% were discharged.

Those who had low albumin levels (2.0%) had a 10 times higher risk of death within 30 days of surgery compared with those who had normal albumin (0.2%). These patients were also more likely to have major (aRR, 2.14; 95% CI, 2.05-2.25) and minor complications (aRR, 1.48; 95% CI, 1.33-1.65). Additionally, blood transfusion was the most common major complication occurring in 12.0% of patients.

For patients with uterine cancer, those who met ACS criteria had an increased length of stay at 3.50 days (95% CI, 2.80-4.20), and minor complications (aRR 2.03, 95% CI 1.48–2.80). Low albumin levels were correlated with poorer outcomes including increased length of stay (2.83 days, 95% CI 2.58-3.08), increased risk of readmission (aRR 2.38; 95% CI 2.10-2.69), reoperation (aRR 2.56; 95% CI 2.01-3.25), major complications (aRR 3.74; 95% CI 3.48-4.02), and minor complications (aRR 2.17, 95% CI 1.90-2.48).

Among those with ovarian cancer, ESPEN2 was associated with increased length of stay by 0.54 days (95% CI, 0.10-0.98). Those who met the ACS criteria had increased length of stay by 1.81 days (95% CI, 1.34-2.29), a higher risk of readmission (aRR 1.36, 95% CI 1.06-1.75), and major complications (RR 1.67, 95% CI 1.52-1.82). Albumin levels of less than 3.5 g/dL were associated with a longer stay by 2.46 days (95% CI, 2.19-2.73), an increased risk of readmission (aRR 1.28; 95% CI 1.11–1.47), reoperation (aRR 1.31; 95% CI 1.01–1.70), and major complications (aRR 1.74; 95% CI 1.65–1.74). Those with cervical cancer who had albumin levels of less than 3.5 g/dL had an increased stay of 4.02 days (95% CI, 2.52-5.51).


Goins EC, Weber JM, Truong T, et al. Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: analysis using a national surgical outcomes database. Gynecol Oncol. 2022;165(2):309-316. doi:10.1016/j.ygyno.2022.01.030

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content